Skip to main content

Table 2 Trends over time in use of low-dose DOAC therapy for non-valvular atrial fibrillation, among patients meeting criteria for full-dose therapy

From: Guideline-discordant dosing of direct-acting oral anticoagulants in the veterans health administration

Year

Should receive full-dose DOAC

Received Low-Dose DOAC

 

Should receive full-dose Dabi

Received Low-Dose Dabi

 

Should receive full-dose Riva

Received Low-Dose Riva

 

Should receive full-dose Apix

Received Low-Dose Apix

 

2010

9

2

22%

9

2

22%

      

2011

1635

37

2%

1635

37

2%

      

2012

2860

79

3%

2814

76

3%

46

3

7%

   

2013

3958

158

4%

3383

92

3%

507

50

10%

68

16

24%

2014

9791

626

6%

5431

104

2%

2904

289

10%

1456

233

16%

2015

18,345

1206

7%

5530

73

1%

5424

389

7%

7391

744

10%

2016

31,327

1971

6%

7344

98

1%

7946

490

6%

16,037

1383

9%

  1. Dabi – dabigatran
  2. Riva – rivaroxaban
  3. Apix - apixaban